Investing in Alliance Pharmaceuticals

At a glance

Our 2023 Performance Overview

182.7 £m See-through Revenue*

31.5 £m Underlying Profit Before Tax*

4.55p Underlying Basic EPS*

180.7 £m Statutory Revenue

-48.8 £m Reported Profit Before Tax

*Non-IFRS Alternative Performance Measures (‘APMs’). See-through revenue includes all sales from Nizoral as if they had been invoiced by Alliance as principal. For statutory accounting purposes the product margin relating to Nizoral sales made on an agency basis is included within Revenue, in line with IFRS 15.

Results centre

2023 Annual Report

Annual Report

Annual Report 2023 (6.3mb)

Built for modern business

An inter-connected network of people and brands

A global range of products delivering outstanding value. Many partners working together; one team, achieving more.

A global business

Headquartered in the UK, with affiliated offices in Europe, the Far East and the US

• Wide international reach through an extensive network of distributors
• Sales in more than 100 countries

Our global locations

Our business model

Our business model sets out how we execute our strategy to deliver on our purpose: empowering people to make a positive difference to their health and wellbeing.

Our business model

Our portfolio

Alliance Pharma holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold worldwide in more than 100 countries.

Our brands